Shanghai UniXell Biotechnology

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Request demo

Shanghai UniXell Biotechnology - overview

About

Based in Shanghai, China, and founded in 2021, Shanghai UniXell Biotechnology operates as a biotechnology company that develops cell therapies for the treatment of various diseases. In March 2022, Shanghai UniXell Biotechnology raised USD 31. 5 million, co-led by new investors CDH Investments and Sherpa Venture Capital, with participation from other new investors Fosun Pharma and TF Capital. Returning and individual investors GL Ventures and Kunlun Capital Pte Ltd also participated in the round.

UniXell offers human pluripotent stem cell (hPSC) technology used for illness simulation and cell replacement therapy. The company develops a pipeline of cell therapies to treat tumors, rare diseases, and neurological disorders like Parkinson's disease, Alzheimer's disease, and stroke. The company plans to use the March 2022 funding for research and development of pipeline products, the construction of clinical-grade cell product production facilities, and the beginning and advancement of clinical trials.

Current Investors

Kunlun Capital, GL Ventures, CDH Investments

Request a demo

Primary Industry

Biotechnology

Sub Industries

Biotechnology

Verticals

HealthTech

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.

Request demo